title: Hepatitis B in rugby: is it time to revisit policy?
authors.affiliation: Division of Hepatology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
authors.forename: Mark W
authors.initials: MW
authors.lastname: Sonderup
authors.affiliation: Constantia Sports Medicine Clinic, Constantiaberg Hospital, Cape Town, South Africa.
authors.forename: Jason
authors.initials: J
authors.lastname: Suter
authors.affiliation: Division of Hepatology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
authors.forename: C Wendy
authors.initials: CW
authors.lastname: Spearman
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D056352:Athletes; D005538:Football; D006509:Hepatitis B / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000627:therapeutic use; D006801:Humans; D008297:Male; D012306:Risk; D000068698:Tenofovir / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D017325:Hepatitis B Vaccines; D000068698:Tenofovir
keywords: Infection; Viral